Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 1 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,581 followers.

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors https://t.co/Klwjcdnj7h

19 Oct 2023

Reply Repost Favourite

10 Oct 2023

Reply Repost Favourite

New research: Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors: Introduction The clinical… #oncology ht

06 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.